Latest C1-inhibitor Stories
Third annual awareness day shines a light on rare, potentially life-threatening condition KING OF PRUSSIA, Pa., May 14, 2014 /PRNewswire/ -- As a Diamond Sponsor of HAE Day on May 16, 2014,
Analysis also reveals decrease in emergency room visits and hospitalizations SAN DIEGO, March 1, 2014 /PRNewswire/ -- Findings announced by CSL Behring today show that current hereditary
International study by CSL Behring is world's first placebo-controlled phase III trial to examine subcutaneous administration of C1-INH for use in treating rare, sometimes life-threatening, condition
- A morbid dread of being buried alive. Also spelled 'taphiphobia'.